PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Aflibercept - Diabetic macular oedema
PAD Profile : Aflibercept - Diabetic macular oedema
Keywords :
DMO
Brand Names Include :
Eylea
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
- Wet age-related macular degeneration
- Lambert-Eaton myasthenic syndrome (LEMS)
- Pain
- Diabetic retinopathy
- Osteoarthritis
- Constipation
- Hepatic encephalopathy
- Travellers diarrhoea
- Penile rehabilitation
- Erectile dysfunction
- Cytomegalovirus
- Hyperuricaemia and Gout
- Vitreomacular traction
- Central retinal vein occlusion
- Peripheral arterial disease
- Dysphagia
- Diarrhoea
- Haemorrhoids
- Heart failure
- Oedema
- Lipid modification
- Haemophilia
- Cataracts
- Branch retinal vein occlusion
- Low sexual desire in menopausal women
- Hypertension
- Hypertension
- Hypertension
- Bacterial infection
- Inflammatory bowel disease
- Psoriasis
- Atopic dermatitis
- Multiple sclerosis
- Myopic choroidal neovascularisation
- Cystic fibrosis
- Fungal infection
- Duchenne muscular dystrophy
- Cystic fibrosis
- Hepatitis C
- Tuberculosis
- Hepatitis C
- Multiple sclerosis
- Tuberculosis
- Hepatitis C
- Hepatitis C
- Hepatitis C
- Haemophilia
- Cystic fibrosis
- Hepatitis C
- Systemic Lupus Erythematosus
- Hepatitis C
- Inclusion body myositis
- Cytomegalovirus
- Haemophilia
- Systemic Lupus Erythematosus
- Duchenne muscular dystrophy
- Hepatitis C
- Haemophilia
- Systemic Lupus Erythematosus
- Haemophilia
- Haemophilia
- Haemophilia
- Haemophilia
- Multiple sclerosis
- Hepatitis B
- Haemophilia
- Short bowel syndrome
- Haemophilia
- Any paediatric use
- von Willebrand deficiency
- Haemophilia
- Haemophilia
- Erectile dysfunction combination therapy
- Children and young people with Epilepsy
- Mental Health disorders
- Mental Health disorders
- Inflammatory bowel disease
- Acne
- Diabetes Mellitus
- Interface Prescribing Policy (IPP)
- Non-acne dermatological indications
- Anticoagulation reversal
- Restless Leg Syndrome
- von Willebrand deficiency
- Immune thrombocytopenia
- Wet age-related macular degeneration
- Bacterial skin and skin structure infections
- Narcolepsy
- Bacterial lung infection (non-cystic fibrosis)
- Lipid modification
- Menopausal disorders
- All
- Raynaud's Phenomenon
- Atopic dermatitis
- Psoriasis
- Clostridioides difficile
- Covid-19
- Covid-19
- Covid-19
- Inflammatory bowel disease
- Growth failure - children
- Inflammatory bowel disease
- Diabetic macular oedema
- Wet age-related macular degeneration
- Diabetic macular oedema
- Migraine (prevention)
- Urinary incontinence
- Immune thrombocytopenia
- Glaucoma / ocular hypertension
- Dry eyes
- Cancer
- Diarrhoea
- Inflammatory bowel disease
- Non-radiographic axial spondyloarthritis
- Photoaggravated dermatoses
- Photodermatoses
- Metabolic disorders
- Insomnia in adults
- Cardiomyopathy
- Epidermolysis bullosa
- Photoaggravated dermatoses
- Psoriasis
- Psoriatic arthritis
- Photodermatoses
- Photodermatoses
- Photoaggravated dermatoses
- Catheter maintenance solutions
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dysphagia
- Prurigo nodularis
- Vitamin D deficiency and insufficiency
- Osteoporosis
- Migraine (prevention)
- Pain
- Ankylosing spondylitis
- Non-radiographic axial spondyloarthritis
- Pustular psoriasis
- Mucus clearance
- Atopic dermatitis
- Alopecia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Smoking cessation
- Pain
- Homozygous familial hypercholesterolaemia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Metabolic disorders
- Concious sedation
- Premedication
- post Bariatric surgery
- Erectile dysfunction
- Parkinson's disease
- Myasthenia gravis
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Tuberculosis
- Tuberculosis
- Tuberculosis
- Covid-19
- Inflammatory bowel disease
- Rehydration in short bowel syndrome
- Faecal impaction (adults)
- Faecal impaction (children)
- Minor digestive complaints
- Haemorrhoids
- Haemorrhoids
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nausea and vomiting
- Agitation in mania and psychotic disorders
- Schizophrenia
- Intraoperative mydriasis / prevention of miosis
- Stoma
- Arrhythmias
- Acute coronary syndrome
- Acute coronary syndrome
- Inotropic support
- IV catheter maintenance
- Cardiopulmonary resuscitation
- Hepatitis D
- Hypertension (severe / crisis)
- Heart failure
- Oedema
- Hypotension
- Tissue glue / suture support
- Diagnosis of Brugada syndrome
- Heparin induced thrombocytopenia
- HIV infection
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Smoking cessation
- Endometriosis
- Surgical diagnostic
- Ocular surgery
- Chronic Obstructive Pulmonary Disease (COPD)
- Growth failure - adults
- Growth failure - children
- Oesophagitis (inducing remission)
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
02 November 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee approve the increased access to THREE switches for existing NICE approved anti-VEGF treatments to optimise response. A Diabetic Macular Oedema (DMO) treatment pathway was also agreed by the APC and is attached for information.
PLEASE NOTE: The most cost-effective anti-VEGF treatment is biosimilar ranibizumab which will be counted as a ‘free switch’ for patients where monthly injections is clinically appropriate.
07 October 2015
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
NICE TA346 was published in July 2015 and the PCN recommends Aflibercept as a treatment option in the treatment of Diabetic Macular Oedema. A treatment pathway will be developed in consultation with local ophthalmologists and will be brought to a future PCN for consideration
Associated BNF Codes
11. Eye
11.08.02. Ocular diagnostic & peri-operative prepn & photodynamic tt